RNA modifications are integral to the regulation of RNA metabolism. One abundant mRNA modification is N 6 -methyladenosine (m 6 A), which affects various aspects of RNA metabolism, including splicing, translation and degradation. Current knowledge about the proteins recruited to m 6 A to carry out these molecular processes is still limited. Here we describe comprehensive and systematic mass-spectrometry-based screening of m 6 A interactors in various cell types and sequence contexts. Among the main findings, we identified G3BP1 as a protein that is repelled by m 6 A and positively regulates mRNA stability in an m 6 A-regulated manner. Furthermore, we identified FMR1 as a sequence-context-dependent m 6 A reader, thus revealing a connection between an mRNA modification and an autism spectrum disorder. Collectively, our data represent a rich resource and shed further light on the complex interplay among m 6 A, m 6 A interactors and mRNA homeostasis. m 6 A was first recognized as an abundant eukaryotic mRNA modification in the 1970s 1,2 , but the functional significance of this modification remained unclear for years. Recently, it was shown that m 6 A is enzymatically added to and removed from mRNA molecules [3] [4] [5] . A heterodimer of METTL3-METTL14, in complex with WTAP, KIAA1429 and ZFP217, catalyzes the addition of a methyl group to adenosine in the context of a conserved consensus sequence (ACU) [5] [6] [7] [8] . Two demethylases, FTO and ALKBH5, are known to remove the m 6 A modification 3,4 . Furthermore, researchers have used antibody-based enrichment methods to determine the transcriptome-wide distribution of m 6 A 9,10 . m 6 A marks several thousand mRNAs in mammalian cells and is enriched at the translation-termination region 9,10 . In recent years, various biological phenomena have been associated with the m 6 A modification on mRNA, such as obesity 11 , plant development 12 , yeast meiosis 13 , cancer 14,15 , cell fate transitions 16 , fertilization 17 and pluripotency 18 . At the molecular level, m 6 A is known to affect mRNA stability 19 , translation [20] [21] [22] , microRNA biogenesis 23 , splicing 11,24 , X-chromosome inactivation 25 and other biological processes 26 .
sequence GGACU 9, 10 . As a control, we used an unmethylated strand (Supplementary Fig. 1a ). We incubated immobilized probes ( Supplementary Fig. 1b-d, Supplementary Table 1 ) with 'light' (L) and 'heavy' (H) SILAC-labeled lysates. Each experiment consisted of a 'forward' and a 'reverse' (label-swap) pulldown. After incubation and washes, bound proteins were subjected to on-bead trypsin digestion and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) ( Supplementary Fig. 1a Readers in mESC (21) Readers in 3T3 (18) g 41 23 
11
Repelled in mESC (52) Repelled in 3T3 (34) 6 A interactors have also been identified in previously published in vivo mRNA-protein interaction studies [37] [38] [39] . Source data for g and h are available online. Proteomics data and GO enrichment analysis are presented in Supplementary Data Set 2.
r e s o u r c e r e s o u r c e which depicts a typical RNA-pulldown interaction plot, shows readers in the upper right quadrant (high forward H/L ratio; low H/L ratio in the reverse experiment). Proteins appearing in the lower left quadrant bound preferentially to the unmodified probe. Background proteins are clustered together around the origin of the plot, and showed ~1:1 ratios in both experiments. We identified 21 m 6 A readers in HeLa nuclear (Fig. 1a) and cytoplasmic (Fig. 1b) lysates. YTH-domain-containing proteins were among the most prominent m 6 A readers (Fig. 1a,b , Supplementary Data Set 2). We identified ALKBH5, an m 6 A demethylase 3 , as a reader for m 6 A-containing RNA, which indicates that our pulldown approach was able to capture putative enzymes involved in m 6 A metabolism. Other prominent m 6 A readers are FMR1 and its paralogs FXR1 and FXR2. We also identified three HNRNP proteins as m 6 A readers in HeLa nuclear lysates. Other HNRNP proteins-namely, HNRNPG 30 , HNRNPC 29 and HNRNPA2B1 (ref. 28)-have previously been linked to m 6 A. These proteins recognize m 6 A in a structure-and sequencedependent context, which is probably why they were missing in our pulldowns. An analysis of Gene Ontology (GO)-term enrichment in m 6 A readers in HeLa cells showed, as expected, that the most enriched biological pathways among m 6 A readers are related to mRNA metabolism and processing (Fig. 1c) .
Epigenetic modifications such as m 5 C not only recruit but also repel proteins 31 . We identified a number of proteins that preferentially interacted with the unmodified RNA sequence and thus are repelled by m 6 A. Prominent among these were two RNA-binding proteins, G3BP1 and G3BP2, both of which are known stress granule proteins 34 , as well as their known interaction partners USP10 and CAPRIN1 (ref. 35 ). This indicates that in our RNA pulldowns we identified both direct RNA-protein interactors and indirect RNA-protein interactors, which are mediated by protein-protein interactions. Another repelled protein is METTL16, which was very recently identified as an adenosine methyltransferase for small nuclear RNA 36 . GO-term enrichment analysis of proteins that are repelled by m 6 A revealed terms related to mRNA splicing and transport (Fig. 1d) .
Although m 6 A levels are mostly stable in different cell types, the m 6 A interactome may vary between different cell types. To address this, we carried out m 6 A pulldowns in mouse embryonic stem cells (mESCs), neuronal progenitor cells and NIH 3T3 cell lysates. In mESCs, Yth proteins, Alkbh5 and Fmr1 proteins represented the most prominent m 6 A readers, which is consistent with data obtained for HeLa cells (Supplementary Fig. 1e,f) . G3bp1 and G3bp2, along with Usp10, again represented the most prominent repelled proteins. RNA pulldowns in mouse neuronal progenitor cell lysates combined with a chemical stable-isotope labeling strategy (dimethyl labeling) once again showed that Yth-domain-containing proteins were conserved, cell-type-independent m 6 A interactors ( Supplementary Fig. 1g,h ). m 6 A interactors in NIH 3T3 cells were similar to those identified in other cell types. Repelled proteins, however, tended to be more diverse and numerous between different cell types ( Supplementary  Fig. 1i, Fig. 1e,f) .
To discriminate between m 6 A readers that are dependent on or independent of the RNA sequence context, we generated two different probes with degenerate sequences surrounding m 6 A and then used these baits for RNA pulldowns in mouse whole cell extracts. From the results, it is clear that YTH-domain-containing proteins largely interacted with m 6 A in an RNA-sequence-context-independent manner, whereas other readers, such as FMR1, showed RNA-sequencecontext-dependent binding. Repelled proteins showed limited overlap between different degenerate strands ( Supplementary Fig. 1j,k) . A global analysis of RNA-binding domains present among m 6 A readers and repelled proteins showed that apart from the YTH domain, the KH, RRM and RBD domains were predominant, which indicates that some of these domains may be regulated by m 6 A directly, albeit in most cases in an RNA-sequence-context-dependent manner (Fig. 1g, Supplementary Fig. 1l) .
Finally, we reasoned that certain proteins identified in our screens may have been identified previously in large-scale mRNA interactome studies, which have been conducted via mRNA-protein cross-linking methodologies in HeLa 37 , HEK293T 38 and mESC 39 mRNA-protein binding resources (Fig. 1h) . A substantial number of the m 6 A readers that we identified in our pulldowns are also covered in these largescale mRNA-protein cross-linking studies, which indicates that at least in some cases, these detected in vivo mRNA-protein interactions are driven or regulated by mRNA modifications such as m 6 A.
Stress granule protein G3BP1 is repelled by m 6 A and regulates mRNA stability One important observation from our pulldown experiments is that many proteins are repelled by the m 6 A modification. The two most consistently and strongly repelled proteins were G3BP1 and G3BP2 (G3BPs). These proteins are known to have critical roles in stress granule assembly 33 and are important for embryonic development. G3BPs have very similar domain structures and contain canonical RNA-binding domains 40 (Fig. 2a) . First, we used recombinant protein to validate preferential G3BP1 binding to the unmodified RNA. We carried out pulldown experiments in two predominant m 6 A sequence contexts: GGm 6 ACU and GAm 6 ACU 41 (Fig. 2b) . In agreement with our quantitative mass spectrometry results ( Fig. 1) , G3BP1 clearly interacted with the GGACU probe, but not with the GGm 6 ACU probe. This methylation-sensitive binding was less clear in the GAACU sequence context (Fig. 2b) . We further verified these results via quantitative mass spectrometry ( Supplementary  Fig. 2a) . Thus, we conclude that G3BP1 is repelled by m 6 A in an RNA-sequence-context-dependent manner.
To identify global mRNA binding sites for G3BP1 and G3BP2, we carried out PAR-CLIP (photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) analyses in HEK293T cells with Flag-tagged constructs (Fig. 2c,d, Supplementary  Fig. 2b) . We identified ~3,800 and ~3,300 mRNA binding sites for G3BP1 and G3BP2, respectively; ~2,300 of these were shared between both proteins (Fig. 2e, Supplementary Data Set 3) . At the transcript level, G3BP1 bound to 2,019 genes, whereas G3BP2 bound to 1,672 genes (Fig. 2e) ; 1,377 target genes were shared between G3BP1 and G3BP2. Most G3BP peaks were found in the 3′-UTR region, followed by intergenic and coding regions (Supplementary Fig. 2c ). As has been observed for m 6 A 10,42 , G3BP-binding sites were enriched at 3′-UTR regions (Fig. 2f) . However, unlike for m 6 A, 5′-UTR regions showed less G3BP binding. The most predominant mRNA-binding motif of G3BP1 was CAACUC (P = 1 × 10 −81 ), whereas CAACUCU was the most predominant binding motif of G3BP2 (P = 1 × 10 −76 ) (Fig. 2g) . These motifs were enriched in 31% and 35% of G3BP1 and G3BP2 binding sites, respectively. Thus, the central part of the known m 6 A consensus sequence (ACU) was conserved among G3BP-binding sites. GOterm enrichment analysis showed that G3BP1-bound mRNAs were significantly enriched for intracellular protein trafficking, mRNA splicing and pre-mRNA processing (Fig. 2h) , whereas G3BP2-bound mRNAs were enriched for intracellular protein trafficking, chromatin packaging and the cell cycle (Supplementary Fig. 2d ). These results indicate that G3BPs regulate mRNAs with both diverse and overlapping biological functions.r e s o u r c e Next, we set out to investigate the potential interplay between m 6 A and G3BP1. Approximately 25% of G3BP1 target genes and 23% of G3BP2 target genes are known to carry m 6 A (Fig. 2i) . On these target genes, the m 6 A site frequently overlaps with the binding site for G3BP1/G3BP2 (88% and 92%, respectively) (Fig. 2j) . This held true in comparisons of G3BP PAR-CLIP data with recently published base-resolution m 6 A data 43 (Fig. 2k) . This indicates that at least a fraction of mRNA G3BP1-and G3BP2-binding sites are direct targets for m 6 A. In certain cases-for example, in a GGACU context-m 6 A would inhibit G3BP binding. To further support this observation, we plotted the distance between G3BP peaks relative to previously reported YTHDF2 and YTHDC1 PAR-CLIP data 19, 24 . This analysis showed that a substantial amount of G3BP and YTHDF2/YTHDC1 peaks overlap, which further suggests that mRNA binding of G3BPs could be regulated by m 6 A ( Supplementary Fig. 2e-h ). However, it should once again be noted that many G3BP1-binding sites occur in a sequence context (AACU) in which methylation may not negatively affect G3BP1 binding.
Given that m 6 A negatively correlates with mRNA stability and that G3BP1 binding to mRNA is negatively affected by m 6 A in certain r e s o u r c e sequence contexts, we reasoned that G3BP1 binding might have a positive effect on the stability of target mRNAs. To address this, we integrated G3BP1 PAR-CLIP data with global mRNA half-life data 44 . First, we assessed the effect of m 6 A on mRNA half-life. As reported previously 19 , we observed a negative correlation between mRNA halflife and m 6 A (Fig. 3a) . Because YTHDF2 is the main effector of m 6 Ainduced mRNA degradation, we also correlated YTHDF2 PAR-CLIP data 19 to mRNA half-life. As was observed for m 6 A, YTHDF2 binding was negatively correlated with mRNA half-life (Fig. 3b) . The effect of YTHDF2 binding on mRNA half-life can be completely explained by the amount of m 6 A on the protein's mRNA targets ( Supplementary  Fig. 3a) . Next, we correlated the effect of G3BP1 binding to the halflife of mRNA targets. Here we observed a significant increase in mRNA half-life concordant with an increasing number of G3BP1 binding sites on target mRNAs ( Fig. 3c ; P < 2.2 × 10 −16 ). To further investigate the role of G3BP1 in regulating mRNA halflife, we carried out G3BP1 expression perturbation experiments combined with RNA-seq ( Fig. 3d-f 
, Supplementary Data Set 4).
We added actinomycin D to cells that contained either reduced or increased amounts of G3BP1 in order to inhibit new mRNA synthesis. Next, we carried out RNA-seq on equal numbers of cells at fixed time points after the addition of actinomycin D. We added an ERCC spike-in to the purified RNA, which, combined with accurate quantification of cell numbers, facilitated absolute mRNA quantification. As expected, G3BP1 knockdown resulted in a significant decrease in the stability of G3BP1 target mRNAs (Fig. 3g) . In agreement with the in silico analysis (Fig. 3c) , the number of G3BP1 binding sites on target mRNA molecules correlated with the stability of those mRNAs. mRNA targets with one G3BP1-binding site showed decreased stability after G3BP1 knockdown, but this effect was more pronounced for targets that contained more than one binding site. In contrast, after G3BP1 overexpression, we observed a small but consistent increase in the stability of target transcripts (Fig. 3g) . We also validated some of these results by qPCR ( Supplementary  Fig. 3b,c) . Together, these results strongly suggest that G3BP1 binding to target mRNAs results in stabilization of the targets. r e s o u r c e Finally, to investigate whether the stabilizing effects of G3BP1 binding to target mRNA molecules can be regulated by m 6 A, we determined mRNA half-lives after METTL3 knockdown alone or in combination with G3BP1 depletion (Fig. 3h) . When m 6 A levels were reduced by METTL3 knockdown, we observed a significant increase in the stability of G3BP1 target mRNAs (Fig. 3i) . This phenocopied the observed effects of G3BP1 overexpression (Fig. 3g) . Combined knockdown of METTL3 and G3BP1 negated this effect (Fig. 3j) . We thus conclude that the increased mRNA stability observed after METTL3 knockdown is at least partially caused by increased G3BP1 binding to these transcripts. In summary, these results reveal the intricate interplay among m 6 A, m 6 A readers, and proteins that are repelled by m 6 A to regulate mRNA stability and turnover.
FMR1 interacts with and regulates translation of m 6 Acontaining transcripts
In both mouse and human cells, we consistently identified FMR1 as an RNA-sequence-context-dependent m 6 A reader (Fig. 1,  Supplementary Fig. 1 ). We first set out to verify this observation by using recombinant protein. As shown in Figure 4a ,b, recombinant FMR1 preferentially bound to the methylated GGACU RNA probe. As a negative control, we used an FMR1 point mutant (I304N) that is known to be defective in mRNA binding. FMR1 contains two N-terminal Agenet domains, three KH domains and one RGG domain, which are known RNA-binding domains 45 . Very recently, it was shown that under certain conditions RGG domains recognize m 6 A-modified RNA 30 . To identify the domain(s) responsible for m 6 A binding, we generated several FMR1 GST-deletion constructs ( Supplementary  Fig. 4a ). RNA pulldowns with these deletion constructs showed that all four RNA-binding domains were needed for preferential m 6 A binding (Supplementary Fig. 4b ). These data thus validate our mass spectrometry data and confirm that FMR1 preferentially interacts with m 6 A-containing RNA in vitro in certain sequence contexts.
FMR1 binds to hundreds of mRNAs to negatively regulate their translation, and loss of FMR1 leads to fragile X-linked mental retardation syndrome 32, 46, 47 . Given the overlap between the m 6 A and FMR1 consensus mRNA sequences (Fig. 4c) 48 and our in vitro interaction data, we asked whether FMR1 preferentially interacts with m 6 A-containing mRNA in vivo. To address this, we first integrated previously published m 6 A-sequencing and FMR1 PAR-CLIP data 10, 48 . We observed clear enrichment of mRNA binding by FMR1 isoforms 1 and 7 on m 6 A sites, suggesting that FMR1 binding may co-occur with m 6 A on mRNA (Fig. 4d) . However, the observed spatial proximity between FMR1 and m 6 A could have been due to overlapping FMR1 and m 6 A consensus motifs, rather than (partially) driven by direct m 6 A binding. To determine whether FMR1 preferentially binds to m 6 A-containing mRNA in vivo, we carried out cross-linking immunoprecipitation followed by quantitative ultra-high-performance liquid chromatography-tandem mass spectrometry (CLIP-UPLC-MS/MS) to directly measure levels of Flag-FMR1-bound m 6 A. We subjected HEK293T cells with stable expression of Flag-FMR1 to UV cross-linking, after which we carried out immunoprecipitation of FMR1 from whole cell extracts. As negative controls, we carried out Flag pulldowns from Flag and Flag-FMR1-I304N cells (Fig. 4e,f,  Supplementary Fig. 4c) . Next, we analyzed immunopurified mRNA samples by mass spectrometry to determine the amount of m 6 A in the samples. We observed specific enrichment of m 6 A (more than two-fold) compared with the input in cells that expressed Flag-FMR1 (Fig. 4g) . Measurements of m 6 A levels in the immunoprecipitated RNA without RiboMinus treatment did not show any significant differences in m 6 A levels among the three samples (Supplementary Fig. 4d ), which indicates that the enriched m 6 A signal was indeed derived from mRNA. Together, these results show that FMR1 colocalizes with m 6 A on mRNA and preferentially interacts with m 6 A-containing mRNA molecules in vivo.
Because FMR1 binds to m 6 A and is known to repress translation by stalling ribosome translocation 47 22, 48 . This analysis revealed significant overlap between the two binding profiles, suggesting that a large subset of target mRNAs are shared (P < 1.259 × 10 −38 ; Fig. 4h) . We even observed significant overlap between FMR1 targets in mouse brain 47 and YTHDF1 targets in HeLa cells (P < 7.120 × 10 −112 ) ( Supplementary  Fig. 4e ), which indicated that many of the overlapping targets are celltype independent. Common targets included HUWE1 and KDM5C, which are also implicated in X-linked mental retardation disorders. GO-term enrichment analysis of common FMR1/YTHDF1 target genes between brain and HeLa cells highlighted biological processes related to neurogenesis (Supplementary Fig. 4f) .
To investigate the potential interplay among FMR1, m 6 A and translation rates, we made use of a pulsed-SILAC-based method 49 ( Fig. 4i, Supplementary Data Set 5) . Briefly, we grew HeLa cells that expressed either inducible FMR1 or FMR1-I304N in light (Lys0Arg0 (K0R0)) medium. We induced transgene expression for 24 h (Fig. 4j) , after which we transferred the induced cells to medium-heavy (M) (K4R6) SILAC medium, whereas we transferred non-induced control cells to heavy (K8R10) SILAC medium. We harvested different batches of cells at 2, 6, 10 and 24 h after transfer to medium-heavy or heavy SILAC medium. The incorporation of SILAC labels during this incubation provided a proxy for the translation rates. Furthermore, comparison of the M/L and H/L ratio for each protein provided a readout for the effect of transgene expression on translation rates (Fig. 4k) . The translation rate was defined as the time needed for half of each quantified protein to be labeled with the given SILAC label 50 . At the global level, FMR1 expression resulted in global translational inhibition compared with the expression of FMR1-I304N (Fig. 4l) . To investigate the potential interplay between the regulation of translation by FMR1 and m 6 A, we carried out a second pulsed-SILAC experiment in which we combined FMR1 or FMR1-I304N expression with simultaneous METTL3 knockdown (Fig. 4j) . As expected, a reduction of m 6 A levels in cells expressing the FMR1-I304N mutant led to decreased translation rates (Fig. 4l) . Notably, the negative effect of wild-type FMR1 expression on translation was aggravated by a simultaneous reduction in the amount of m 6 A (Fig. 4l, Supplementary Fig. 4g ). We interpret this as follows: YTH-domain-containing proteins are strictly dependent on m 6 A for mRNA binding. Their positive effects on translation are therefore mitigated by METTL3 knockdown and the concomitant reduction of m 6 A levels. FMR1 preferentially binds m 6 A-containing mRNA, but it is not strictly dependent on m 6 A for mRNA binding (Fig. 4a) . On the basis of our results, we propose that YTHDF1 and FMR1 compete for binding to m 6 A sites on mRNA. Thus, after METTL3 knockdown, the inhibitory effects of FMR1 on translation rates become even more pronounced, because many putative ACUcontaining FMR1-binding sites become available in the absence of YTHDF1/3. These results further illustrate the complex interplay among m 6 A, m 6 A readers and mRNA homeostasis. r e s o u r c e
DISCUSSION
Here we describe a systematic mass-spectrometry-based proteomics screen to identify m 6 A readers in a variety of cell types and different RNA sequence contexts. Our data show that YTH-domain-containing proteins are evolutionarily conserved cell-type-independent m 6 A readers. In addition, we identified a number of previously unrecognized m 6 A readers, although we emphasize that almost all of these newly identified readers, including FMR1, interact with m 6 A in a manner that is dependent on RNA sequence, and possibly also the secondary structure context. Multiple RNA-binding domains may be responsible for these RNA-sequence-dependent m 6 A interactions, such as the KH and RGG domains. Additional biochemical studies are clearly needed to further investigate this. These observations are analogous to what has been observed for DNA-methylation readers. DNA methylation is read by a few DNA-sequence-independent domains 31 . In addition, other domains, such as the Forkhead box, Krueppel-like zinc fingers and the homeobox, interact with methylated DNA sequences in a DNA-sequence-dependent manner. One important conclusion from our work is that m 6 A could serve to repel proteins from binding to m 6 A-containing mRNA sequences. This is again analogous to what has been observed in the context of DNA methylation 31 . For RNA sequences that contained ACU motifs, we observed a lot of interacting proteins, and for a substantial number of those, binding was inhibited when the adenosine base in the sequence was methylated. The most strongly repelled proteins in our RNA pulldown experiments were G3BP1 and G3BP2. However, this phenomenon seems to be dependent on the RNA sequence context. In a GGACU context, m 6 A strongly repelled G3BP1 binding, whereas inhibition of binding was not obvious when methylation occurred in a GAACU context (Fig. 2b) . The results of our functional experiments for G3BP1 (Figs. 2 and 3) suggest that G3BP1 binding to mRNA is positively correlated with mRNA stability, and that this positive correlation can be affected by manipulation of m 6 A levels. mRNA stability in cis is mediated by three major factors: (1) the extent of m 6 A presence, (2) polyadenylation and (3) codon optimization 51 . Of these three factors, m 6 A is the only one that can be dynamically altered through methylation and demethylation. The cis factors are aided by trans factors such as protein readers, which regulate the stability of mRNA. It was previously reported 19 that YTHDF2 predisposes mRNA to degradation in an m 6 A-dependent manner. Our data suggest that G3BP1 is one additional m 6 A-regulated factor that affects RNA stability. G3BP1 could stabilize mRNA molecules in several ways. G3BP1 is found in the nucleus in resting cells 52 , and it could bind to newly transcribed mRNA molecules in the nucleus and prevent methylation by competing with the m 6 A methylation machinery. Alternatively, G3BP1 could bind to its target mRNAs in the cytoplasm and form ribonucleoprotein granules (RNPs). These RNPs could assemble into higher-order stress granules consisting of other proteins and translation factors 53 . The formation of G3BP1-mRNA RNPs or stress granules could prevent access to the RNA degradation machinery, thereby protecting mRNA. Another possible mechanism is that under certain conditions, cells could demethylate mRNA, thereby allowing G3BP1 to bind to GGACU-containing mRNA sequences, resulting in increased stability of those mRNA molecules. Interestingly, G3BP1 is also known to bind inosine 54 , a modified adenosine base, which indicates a broader role for G3BPs in RNA-modification-dependent modulation of mRNA homeostasis. In any case, our findings reveal intricate interplay between RNA-binding proteins and the regulation of mRNA homeostasis. Dynamic m 6 A levels in cells, which affect many RNA-binding proteins, seem to represent a regulatory switch via which mRNA stability and translation can be quickly fine-tuned to regulate gene expression and cell function in the presence of cellular stimuli and perturbations.
The work presented here is also relevant from a clinical perspective. It is well established that m 6 A has an important role in the regulation of mRNA homeostasis. It is therefore not surprising that disturbances of readers, writers and erasers of m 6 A are implicated in a number of diseases, including obesity and cancer 14, 15 . We have identified FMR1, an important constituent of neuronal granules and stress granules 55 , as a clinically relevant, RNA-sequence-context-dependent reader for m 6 A. FMR1 binds to ribosomes and represses the translation of target mRNAs. Loss of this repression in neurons due to the absence of functional FMR1 leads to fragile X-linked mental retardation 47 . Our work suggests that a reduction of m 6 A levels or inhibition of YTHDF1, both of which inhibit mRNA translation, may result in the alleviation of disease symptoms in fragile X-linked mental retardation syndrome. Further work, however, is clearly needed to test this hypothesis. In any case, our work here has uncovered what is, to the best of our knowledge, the first reported link between an mRNA modification and an autism spectrum disorder, thus paving the way toward a better molecular understanding, and possibly treatment, of this disease.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Cell culture, SILAC labeling and cell-extract preparation. HeLa, HEK293T and NIH 3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo) supplemented with 10% FBS (Gibco), 1× penicillin-streptomycin (15140-122; Thermo) and 1 mM glutamine (Invitrogen). The cells were regularly tested in-house for the presence of mycoplasma. HeLa cells were SILAC-labeled by culture in SILAC DMEM (88420; Thermo) supplemented with 10% dialyzed FBS (DS-1003; Dundeecell), 1× Glutamax (35050-061; Thermo), 1× penicillinstreptomycin, 73 mg/mL l-lysine (light/K0, Sigma, A6969; or heavy/K8, Sigma, 608041) and 29.4 mg/mL arginine (light/R0, Sigma, A6969; or heavy/R10, Sigma, 608033). ESCs were grown in serum-free 2i medium. Briefly, we prepared serumfree ESC medium by mixing the following components: Neurobasal medium (Gibco; 21103-049), 250 mL; DMEM/F12 (Gibco; 11320-033), 250 mL; N2-Supplement (Gibco; 17502-048), 2.5 mL; B27 minus RA (Gibco; 12587001), 5 mL; 7.5% BSA (Gibco,;15260-037), 3.33 mL; penicillin-streptomycin, 5 mL; 1 mM glutamine (Invitrogen); 1% nonessential amino acids (Invitrogen); 6.3 µl monothioglycerol (M6145; Sigma); LIF (1,000 U/mL); and CHIR99021 and PD0325901 (3 and 1 µM, respectively) . For SILAC labeling of ESCs, we used custom-made Neurobasal and DMEM/F12 (Life technologies) without lysine and arginine. Mouse neuronal progenitor cells were cultured as described previously 56 .
Whole cell lysates for RNA pulldowns were prepared according to the following protocol: Cells were harvested with trypsin and washed twice with chilled PBS. Cells were then resuspended in five pellet volumes of whole cell extract buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5 mM DTT, 10% glycerol, and protease inhibitor cocktail) and incubated for 90 min at 4 °C on a rotating wheel. Crude lysates were then centrifuged for 30 min at 14,000 r.p.m. at 4 o C. Soluble whole cell extracts were finally aliquoted and snap-frozen in liquid nitrogen until further usage. Nuclear and cytoplasmic extracts were prepared as described previously 56 . Cell lysates for western blots were prepared with RIPA buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 150 mM NaCl, 0.1% SDS and protease inhibitor cocktail). Protein quantification was performed with a Bradford or BCA kit (Thermo) according to the manufacturer's protocol.
Plasmids and constructs. G3BP1 cDNA was cloned into the HindIII and BamHI sites of pcDNA3-c-Flag vector (Plasmid #20011; Addgene) to create an expression construct with a C-terminal Flag tag. For the creation of N-terminally GST-tagged constructs, G3BP1 cDNA was amplified from HeLa cDNA and cloned into pGEX-5X1 vector (GE Healthcare). FMR1 isoform 1 (pFRT-TODestFLAGHAhFMRPiso1; 48690) and FMR1-I304N isoform 1 (pFRT-TODestFLAGHAhFMRPiso1I304N; 48692) vectors were obtained from Addgene. FMR1, FMR1-I304N and various domains of FMR1 were amplified from these vectors. We created FMR1 overexpression constructs for the creation of doxycycline-inducible HeLa cell lines by subcloning FMR1 and FMR1-I304N in AAVS1-TRE3G-EGFP (Addgene; 52343). A Kozac sequence and a Flag-HA tag were added to the N terminus of FMR1 and FMR1-I304N by PCR. AAVS1-TRE3G-EGFP 57 contains an inducible promoter and AAVS1 homology arms for correct integration. By cloning FMR1 in SalI and MluI sites, we generated an AAVS1-TRE3G-FMR1 construct. Primer sequences used to amplify specific genes and constructs are listed in Supplementary Table 1. Generation of cell lines. We generated HeLa cells expressing inducible FMR1 and FMR1-I304N by knocking Flag-HA-FMR1 or the I304N mutant into the AAVS1 locus. To this end, HeLa cells were transfected with a donor vector (AAVS1-TRE3G-FMR1) and a CRISPR-Cas9 vector with guide RNAs targeting the AAVS1 locus 58 , using Lipofectamine 3000 (Invitrogen). In this system, cells with correct integration at the AAVS1 locus become puromycin resistant. Cells with stably integrated gene products were selected by puromycin (1 µg/mL) selection for several days. Individual colonies were picked, and doxycyclineinduced expression was tested for several clones. Overexpression of FMR1 and FMR1-I304N was induced by the addition of 1 and 0.5 µg/mL doxycycline, respectively.
Recombinant protein expression and purification. Rosetta BL-21 bacteria (Novagen) were used for GST-fusion protein expression. Cells were grown in LB medium supplemented with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol. IPTG was added to a final concentration of 0.5 mM, after which protein expression was induced for 4 h or overnight at 16 °C. Cells were then harvested, washed with PBS and resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 15% glycerol, 1 mM EDTA, 0.5 mM PMSF, 1 mM DTT, 100 mM NaCl, 1% Triton X-100, 0.25% NP-40, protease inhibitor cocktail, and lysozyme to a final concentration of 0.5 mg/ml). Cells were lysed by repeated (five times) freezethaw cycles. Bacterial debris was removed by centrifugation at 14,000 r.p.m. for 20 min at 4 °C, after which soluble extracts were aliquoted and snap-frozen in liquid nitrogen until further usage.
SILAC-based RNA pulldowns. All buffer solutions were prepared with highquality, RNase-free reagents. Each SILAC-based RNA pulldown experiment consisted of four individual pulldowns. 10 µl of streptavidin Sepharose highperformance beads (GE Healthcare) were used for each pulldown (20 µl of 50% slurry). Beads were first washed twice in 1 mL of RNA binding buffer (50 mM HEPES-HCl, pH 7.5, 150 mM NaCl, 0.5% NP40 (v/v), 10 mM MgCl 2 ). After each wash step, samples were centrifuged for 3 min at 4,000 r.p.m. in a pre-cooled (4 o C) tabletop centrifuge to spin down the beads. To inactivate and remove RNases, we incubated the beads with RNase inhibitor RNasin plus (Promega) in RNA binding buffer (100 µl buffer with 0.8 units of RNasin/µl) for 30 min on ice. After centrifugation and removal of RNasin-RNase complexes, beads were preblocked with yeast tRNA (50 µg/mL; AM7119; Life Technologies) in RNA binding buffer overnight at 4 °C on a rotation wheel. The preblocked beads were washed twice with RNA binding buffer and then incubated with 5 µg of biotinylated RNA probe (per pulldown) diluted with RNA binding buffer to a final volume of 600 µl. Beads were incubated for 30 min at 4 °C in a rotation wheel to allow binding of biotinylated probes to the streptavidin beads. The beads were washed once with 1 mL of RNA wash buffer (50 mM HEPES-HCl, pH 7.5, 250 mM NaCl, 0.5% NP-40 and 10 mM MgCl 2 ) and twice with protein incubation buffer (10 mM Tris-HCl, pH 7.5, 150 mM KCl, 1.5 mM MgCl 2 , 0.1% (v/v) NP-40, 0.5 mM DTT, and complete protease inhibitors −/− EDTA (Roche)). Beads containing immobilized RNA were then incubated with 600 µg of nuclear extract or 1,000 µg of cytoplasmic extracts in a total volume of 600 µl of protein binding buffer. The incubation reaction also contained 30 µg of yeast tRNA to prevent nonspecific binding, and RNasin. In the forward experiment, the control probe was incubated with light-labeled (R0K0) lysates, whereas the m 6 A probe was incubated with heavy (R10K8) lysates. The reverse experiment represented a biological-replicate label swap. The reactions were incubated at room temperature for 30 min and then for 90 min on a rotation wheel at 4 °C. The beads were then washed three times with protein incubation buffer and twice with ice-cold PBS to remove detergent from the beads. The last PBS wash was used to combine beads from the forward and the reverse pulldowns as follows:
Forward reaction: control probe, R0K0 (light); m 6 A probe, R10K8 (heavy) Reverse reaction: control probe, R10K8 (heavy); m 6 A probe, R0K0 (light)
Proteins were on-bead digested with trypsin. Briefly, beads were resuspended in 100 µL of elution buffer (50 mM Tris, pH 8.5, 2 M urea and 10 mM DTT) and then incubated for 20 min at room temperature in a thermoshaker at 1,100 r.p.m. Iodoacetamide was then added to a final concentration of 55 mM, and the mixture was incubated for 10 min in a thermoshaker (1,100 r.p.m.) at room temperature in the dark. Proteins were then partially digested from the beads by the addition of 250 ng of trypsin for 2 h at room temperature in a thermoshaker in the dark. After incubation, the supernatant was collected in a separate tube. The beads were then incubated with 50 µL of elution buffer for 5 min at room temperature in a thermoshaker (1,100 r.p.m.). 100 ng of fresh trypsin was added to the pooled eluates, and proteins were digested overnight at room temperature. Finally, tryptic peptides were acidified to pH <2 with TFA (10%) and desalted with C18 Stage tips before MS analyses.
Dimethyl-labeling-based RNA pulldowns. Dimethyl-labeling-based RNA pulldowns were performed with unlabeled lysates. Tryptic peptides from individual pulldowns obtained after on-bead digestion were differentially labeled with dimethyl isotopes (CH 2 O or CD 2 O) essentially as described 59 . We created forward and reverse reactions by mixing labeled peptides as follows: MaxQuant output tables for the forward and reverse pulldowns. Outliers were identified independently in the forward and reverse pulldowns by means of box plot statistics (threshold: 1.5× the interquartile range). Proteins were considered significant if they were identified as outliers in both experiments. Proteins identified in MaxQuant output tables were classified into four groups: readers, repelled proteins, background proteins, and contaminants. For whole-cell proteome experiments, we used a Swiss-Prot curated database for identification (downloaded on 7 February 2016). Scatter plots were generated in R.
Pulsed SILAC. Pulsed SILAC is a variant SILAC method used to measure translation rates in cells 49 . HeLa cells expressing FMR1 under doxycycline control were SILAC-labeled in light medium (K0R0) for a week to allow them to adapt to the culture conditions. Doxycycline was added for 24 h to induce expression of FMR1 or the FMR1 mutant. Cells without doxycycline induction served as a control. In the case of FMR1 overexpression combined with METTL3 knockdown, METTL3 siRNAs were transfected 24 h before the addition of doxycycline. Control siRNA was transfected into control cells that were not treated with doxycycline. 24 h after doxycycline induction, cells were washed with PBS to remove any light amino acid-containing medium. Cells with FMR1 overexpression alone or in combination with with METTL3 knockdown were transferred to medium-heavy (K4R6) medium. Non-doxycycline-treated control cells were transferred to heavy (K8R10) medium. Cells were subsequently harvested 2, 6, 10 and 24 h after transfer into medium-heavy or heavy SILAC medium. The harvested cells were then lysed on ice by the addition of 150 µl of lysis buffer (100 mM Tris-HCl, pH 7.6, 4% SDS) and heated for 5 min at 95 °C. The samples were sonicated with a Diagenode Bioruptor to reduce viscosity. Crude lysates were then centrifuged at 14,000 r.p.m. for 20 min, and supernatants were recovered. Lysate protein concentrations were measured with the BCA kit (Thermo). Equal amounts of protein from control and treated samples at each time point were then mixed. DTT was added to a 100 mM final concentration, and the samples were incubated for 15 min. Samples were then further processed via the FASP method 70 . A trypsin-LysC mix (Promega) was used for digestion. Finally, tryptic peptides were acidified to pH <2 with TFA (10%) and desalted with C18 Stage tips before MS analyses.
The time it took for half the protein to be labeled (THPL) was calculated for all identified proteins as described by Visscher et al. 50 . In short, we performed a linear regression between the log-transformed fraction of labeled protein and the pulse time. We then extrapolated the THPL by dividing the slope of the regression by log(0.5). In addition to the four pulsed time points, we forced the regression lines though zero as described previously 50 . To ensure high confidence of our individual THPL measurements, we used only the proteins with an identified label ratio in all time points and a Pearson correlation coefficient of 0.95 or higher for downstream analyses.
Statistical analysis.
Various statistical methods were used as appropriate and are indicated in the figure legends. The interquartile range (1.5×) was used to identify outliers in affinity-purification mass spectrometry experiments. The P values of the identified RBP motifs were determined by HOMER 63 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
MaxQuant was used to analyse the mass spectrometry based proteomics data. PAR-CLIP data was aligned and analysed with TopHat2 and Paralyzer, respectively. RNA-Seq for mRNA half-lives determination was analyzed with kallisto.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
The cell lines we generated are freely available to the scientific community.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
We used commercial antibodies only: G3BP1 (Santa Cruz biotechnology, sc-98561), FLAG (Sigma-Aldrich, F1804), GST (Thermo, MA4-004) and METTL3 (Bethyl laboratories, A301-567-A). The G3BP1 antibody was validated using FLAG-tagged G3BP1 overexpression lysates and western blotting. FLAG and GST antibodies are routinely used in our laboratory and tested by western blotting on overexpression lysates. METTL3 antibody was tested by knocking down METTL3 using 3 different siRNAs followed by western blotting of whole cell lysates.
Eukaryotic cell lines
a. State the source of each eukaryotic cell line used. HeLa Kyoto, mouse R1 ESCs, NIH 3T3 and HEK cell lines were obtained from the inhouse cell line repository at Radboud Institute of Molecular Life Sciences. All these cell lines can be commercially obtained from ATCC. Mouse NPCs were generated by in vitro differentiating R1 mouse ESCs using standard protocols.
b. Describe the method of cell line authentication used. None of the cell lines used were authenticated.
c. Report whether the cell lines were tested for mycoplasma contamination.
All our cell lines in culture are tested for mycoplasma contamination every month. Of all the cell lines we used, only HEK cells are present in ICLAC database. We used these cells to generate data that we then could compare to previously published datasets in the same cell line.
